Brokerages expect LeMaitre Vascular Inc (NASDAQ:LMAT) to post sales of $30.49 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for LeMaitre Vascular’s earnings. The highest sales estimate is $30.51 million and the lowest is $30.47 million. LeMaitre Vascular posted sales of $28.39 million in the same quarter last year, which suggests a positive year-over-year growth rate of 7.4%. The business is expected to announce its next quarterly earnings report on Tuesday, February 18th.

On average, analysts expect that LeMaitre Vascular will report full year sales of $117.57 million for the current year, with estimates ranging from $117.53 million to $117.60 million. For the next fiscal year, analysts forecast that the business will post sales of $129.66 million, with estimates ranging from $128.70 million to $130.25 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, October 23rd. The medical instruments supplier reported $0.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.04. The company had revenue of $29.10 million for the quarter, compared to analyst estimates of $28.15 million. LeMaitre Vascular had a net margin of 16.76% and a return on equity of 13.38%. The firm’s revenue was up 20.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.21 earnings per share.

Several research analysts have issued reports on the company. ValuEngine cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Monday, October 7th. First Analysis cut LeMaitre Vascular from a “strong-buy” rating to an “outperform” rating and raised their price target for the company from $37.00 to $40.00 in a research report on Thursday, October 24th. BidaskClub upgraded LeMaitre Vascular from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, November 27th. Barrington Research restated an “outperform” rating on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. Finally, Zacks Investment Research upgraded LeMaitre Vascular from a “hold” rating to a “strong-buy” rating and set a $40.00 price target for the company in a research report on Saturday, October 26th. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the stock. LeMaitre Vascular presently has an average rating of “Buy” and a consensus target price of $39.25.

In related news, CFO Joseph P. Pellegrino, Jr. sold 64,792 shares of LeMaitre Vascular stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $35.88, for a total transaction of $2,324,736.96. Following the completion of the sale, the chief financial officer now owns 211,878 shares in the company, valued at approximately $7,602,182.64. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO George W. Lemaitre sold 7,068 shares of LeMaitre Vascular stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $37.17, for a total value of $262,717.56. Following the sale, the chief executive officer now owns 3,089,687 shares of the company’s stock, valued at approximately $114,843,665.79. The disclosure for this sale can be found here. In the last quarter, insiders have sold 237,435 shares of company stock valued at $8,408,790. 19.60% of the stock is currently owned by company insiders.

A number of large investors have recently modified their holdings of LMAT. Russell Investments Group Ltd. boosted its stake in LeMaitre Vascular by 92.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 360,859 shares of the medical instruments supplier’s stock worth $12,333,000 after buying an additional 173,214 shares during the last quarter. Copeland Capital Management LLC boosted its stake in LeMaitre Vascular by 38.7% in the 3rd quarter. Copeland Capital Management LLC now owns 536,199 shares of the medical instruments supplier’s stock worth $18,327,000 after buying an additional 149,642 shares during the last quarter. GW&K Investment Management LLC acquired a new stake in LeMaitre Vascular in the 2nd quarter worth about $3,734,000. Morgan Stanley boosted its stake in LeMaitre Vascular by 151.7% in the 2nd quarter. Morgan Stanley now owns 202,672 shares of the medical instruments supplier’s stock worth $5,671,000 after buying an additional 122,152 shares during the last quarter. Finally, Nuveen Asset Management LLC acquired a new stake in LeMaitre Vascular in the 2nd quarter worth about $2,612,000. 79.17% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:LMAT opened at $35.37 on Tuesday. The stock has a fifty day moving average price of $34.63 and a two-hundred day moving average price of $31.34. The stock has a market capitalization of $711.09 million, a price-to-earnings ratio of 42.11, a PEG ratio of 4.02 and a beta of 1.21. LeMaitre Vascular has a 1 year low of $21.79 and a 1 year high of $37.35.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Wednesday, November 20th will be given a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date is Tuesday, November 19th. LeMaitre Vascular’s dividend payout ratio is presently 40.48%.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Read More: Understanding Market Liquidity

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.